Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome

Affiliations

• ¹ Division of Haematology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
• ² Department of Haematology, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
• ³ Division of Haematology/Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea.
• ⁴ Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
• ⁵ Department of Haematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.
• ⁶ Division of Oncology and Haematology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.
• ⁷ Division of Haematology, Department of Internal Medicine, Kosin University College of Medicine, Kosin University Gospel Hospital, Busan, Korea.
• ⁸ Division of Haematology and Cellular Therapy, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
• ⁹ Division of Haematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Korea.
• ¹⁰ Division of Haemato-oncology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.
• ¹¹ Department of Haematology/Oncology, Soonchunhyang University Hospital, Seoul, Korea.
• ¹² Division of Haematology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
• ¹³ Department of Haematology, Catholic Haematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.